Pharmadax Receives FDA Approval for a Generic Version of Seroquel XR

Tuesday, May 16, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

Pharmadax Inc. received FDA approval for a generic version of Seroquel XR (quetiapine fumarate extended-release) tablets on May 9, 2017

IRVINE, Calif., May 16, 2017 /PRNewswire/ -- Pharmadax Inc., a pharmaceutical company based in New Taipei City,

Taiwan, and its subsidiary Pharmadax USA, Inc., based in Irvine, California, today announced that U.S. Food and Drug Administration (FDA) has approved a generic equivalent to Seroquel XR (quetiapine fumarate) ER tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg. Pharmadax has launched the product with their Marketing Partner, TruPharma LLC.

Seroquel XR is a once-daily tablet indicated for the treatment of schizophrenia; acute depressive episodes in bipolar disorder; acute manic or mixed episodes in bipolar disorder alone or with lithium or divalproex; and adjunctive therapy to antidepressants for patients with major depressive disorder (MDD).

According to IMS Health data, U.S. sales of Seroquel XR and generic equivalents for the 5 strengths to be marketed by TruPharma LLC were approximately $1.34 billion for the 12 months ended December 31, 2016.

Yipin Huang, Chairman of Pharmadax Inc., stated: "We are very excited to receive approval of our first controlled-release product, and second overall approval by the US FDA. Launching this product in the US market is a major milestone for Pharmadax. Leveraging on our unique business model and technology platform, we look forward to providing more affordable and high quality complex dosage forms to the American public."

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pharmadax-receives-fda-approval-for-a-generic-version-of-seroquel-xr-300457977.html

SOURCE Pharmadax Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook